Moleculin reports Q3 2023 cash of $24.6M; advances Annamycin in AML and STS

Moleculin Biotech, Inc.

Cash and equivalents $24.6M as of Sep 30, 2023; runway estimated into Q3 2024.
R&D expense $3.3M, down 45% YoY from $6.0M; G&A $2.6M, down 16% from $3.1M.
Dosed first subjects in Phase 2 trial of Annamycin + Cytarabine for AML (MB106).
Completed enrollment in U.S. Phase 1b/2 trial of Annamycin for STS lung metastases (MB107).
Independent assessment confirmed absence of cardiotoxicity in Annamycin-treated subjects.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Moleculin Biotech, Inc. reported financial results for the quarter ended September 30, 2023.

Period: the quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 13, 2023, Moleculin Biotech, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2023

View on SEC.gov

18 earnings releases filed in the last 30 days. Browse all earnings releases →

Moleculin Biotech, Inc. filing history →

Source: SEC EDGAR

accession 0001437749-23-031390

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.